💥 Dragon Pharma

B7-33

✔️ Substance: Relaxin Receptor 1 Agonist
✔️ Price For: Vial 6 mg
✔️ Brand: Dragon Pharma

Out of stock

Dragon Pharma B7-33

IDENTITYCompoundB7-33
SubstanceRelaxin Receptor 1 Agonist
Strength6 mg
FormLyophilized Vial
ClassResearch Peptide Compound

PEPTIDE PROFILETargetRXFP1 Relaxin Receptor
OriginRelaxin-derived peptide fragment
ActivityRelaxin pathway modulation
Research AreaCardiovascular & Tissue Biology
StatusInvestigational Compound

PHARMACOLOGYMechanismRXFP1 receptor activation
PathwayRelaxin signaling
AdministrationSubcutaneous (SC) injection
ReleasePeptide activity profile
ResearchExperimental use

STORAGE & PACKAGEBrandDragon Pharma
Package6 mg Multi-dose Vial
Storage2–8°C Recommended
After ReconstitutionRefrigerated Storage
Protect FromLight & Heat

ADMINISTRATION RouteSubcutaneous (SC)
PreparationReconstitution Required
Injection SiteAbdominal Area / SC Tissue
FrequencyResearch protocols vary
FormFreeze-dried peptide

USAGE PROFILEResearch Duration4–12 Weeks
Activity OnsetGradual peptide response
Peak Research WindowSeveral Weeks
Usage TypeExperimental peptide research
Daily UseProtocol dependent

DOSING INFORMATIONResearch Range50–200 mcg/day
Weekly Amount0.35–1.4 mg/week
Beginner Research50 mcg/day
Intermediate100 mcg/day
Advanced Research200 mcg/day

BODYBUILDING USAGECategoryRecovery Support Research
Primary InterestTissue Recovery Pathways
Muscle SupportIndirect Relaxin Signaling Effects
Training PhaseRecovery Focused Programs
CombinationPeptide Research Protocols

RECOVERY PROFILERecovery PathwayRelaxin Receptor Signaling
Tissue ResearchConnective Tissue Biology
InflammationResearch Interest
Muscle RepairIndirect Support Research
PCTNot Applicable

COMPATIBILITYPeptide ResearchOther Investigational Peptides
GH PathwayResearch Combination Area
RecoveryTraining Support Research
NutritionProtein & Recovery Focus
PCTNot Required

MECHANISM OF ACTIONReceptorRXFP1
SignalRelaxin Pathway Activation
Biological EffectCellular Signaling Modulation
Target SystemVascular & Connective Tissue
ClassPeptide Agonist

PHARMACOKINETICSAbsorptionPeptide Injection Route
MetabolismProteolytic Breakdown
ClearancePeptide Degradation Pathways
Half-lifeLimited Human Data
ExposureShort Peptide Activity Profile

SAFETY PROFILEClinical StatusInvestigational Compound
Human DataLimited Research Information
Immune ResponsePotential Peptide Sensitivity
Monitoring Laboratory Evaluation Recommended
Long-Term DataNot Established

CONTRAINDICATIONSPregnancyNot Recommended
BreastfeedingAvoid Use
Cardiovascular Medical Assessment Required
AllergyPeptide Hypersensitivity Risk
Medical ConditionsProfessional Evaluation

CHEMICAL PROFILECompoundB7-33 Peptide
TargetRelaxin Family Peptide Pathway
ReceptorRXFP1
StructureSynthetic Relaxin Fragment
ClassificationPeptide Research Compound

OVERVIEW

Dragon Pharma B7-33 6 mg is a research peptide compound designed to activate the relaxin receptor 1 (RXFP1) pathway. B7-33 is a synthetic peptide fragment derived from relaxin-related research and has been investigated for its potential effects on cellular signaling, vascular biology, extracellular matrix regulation and tissue remodeling pathways.

POTENTIAL BENEFITS

RXFP1 receptor activation research
Connective tissue biology investigation
Relaxin pathway modulation
Cellular signaling research interest
Potential vascular biology applications
Experimental recovery pathway research

POTENTIAL RISKS

Limited human safety information
Unknown long-term effects
Possible injection site reactions
Potential immune response
Experimental compound classification
Insufficient clinical bodybuilding data

PERFORMANCE PROFILE

Recovery Support

70%

Tissue Research

82%

Direct Muscle Gain

15%

Fat Loss

10%

Connective Tissue

75%

WHY CHOOSE DRAGON PHARMA

Dragon Pharma products are selected by some users because of brand recognition, pharmaceutical-style presentation and availability of specialized compounds used in research-focused environments. For peptide products such as B7-33, important quality factors include accurate labeling, proper vial presentation, controlled storage requirements and transparent product information.

WHAT IS DRAGON PHARMA?

Dragon Pharma is a pharmaceutical-style brand recognized within bodybuilding and sports supplement communities for producing a range of performance-related products including research compounds, peptides and other specialized formulations.

Products associated with Dragon Pharma are commonly marketed toward athletes interested in advanced performance science, although research compounds such as B7-33 remain outside standard approved medical applications. Product quality, storage conditions and responsible handling are important considerations for any peptide-based material.

CONCLUSION

Dragon Pharma B7-33 6 mg is an experimental relaxin receptor 1 agonist peptide designed for research involving RXFP1 signaling pathways.

Unlike anabolic hormones, B7-33 does not directly stimulate androgen receptors or increase muscle protein synthesis through traditional anabolic mechanisms. Its main scientific interest relates to relaxin biology, tissue remodeling, vascular pathways and cellular communication.

Within bodybuilding and athletic research communities, B7-33 is primarily discussed as a recovery-oriented peptide due to interest in relaxin-related biological processes rather than direct anabolic activity. Unlike anabolic steroids or growth hormone compounds, B7-33 does not function through androgen receptors or GH/IGF-1 stimulation.

Disclaimer

This content is provided exclusively for educational and informational purposes. B7-33 is an investigational peptide compound and is not approved as a bodybuilding medication or performance-enhancing treatment. The information presented does not constitute medical advice, diagnosis, treatment recommendations or endorsement of non-medical use.

Research compounds should only be evaluated according to applicable scientific, medical and legal standards. Individuals should consult qualified healthcare professionals regarding health decisions, laboratory monitoring and applicable regulations in their jurisdiction.